Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of YKL-40 as glioblastoma biomarker

A technology of YKL-40, brain glioma, which can be used in the determination/inspection of microorganisms, biological testing, biochemical equipment and methods, etc., and can solve problems such as lack of chitinase ability

Inactive Publication Date: 2017-11-24
BEIJING TRICISIONBIO THERAPEUTICS INC
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Structural analysis revealed that YKL-40 contains a highly conserved chitin-binding domain, however, it is functionally deficient as a chitinase due to its glutamate-to-leucine mutation in the chitinase catalytic domain [2,3]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of YKL-40 as glioblastoma biomarker
  • Application of YKL-40 as glioblastoma biomarker
  • Application of YKL-40 as glioblastoma biomarker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] TCGA data analysis

[0024] The present invention uses Oncomine Outlier to analyze the YKL-40 expression levels of 542 GBM patients in the TCGA database.

[0025] The results showed that, compared with normal brain tissue, the expression level of YKL-40 in 542 glioma patients in the TCGA database was significantly increased, foldchange=9.483, Pfigure 1 ).

Embodiment 2

[0027] Validation of qPCR in 45 Chinese patient populations

[0028] The present invention further collected lesion resection tissue samples of 45 patients with glioblastoma who had undergone surgical treatment and had complete medical history data. They had been diagnosed as glioblastoma by the pathology department. There were 32 male cases and 13 female cases; according to WHO tumor Classification, all 45 patients were grade IV. The normal control tissues were 9 cases of normal brain tissues, all of which were from donors.

[0029] 3. RNA extraction and cDNA synthesis

[0030] After grinding the tumor tissue with liquid nitrogen, use the Trizol reagent extraction method to extract the total tissue RNA, and then use the reverse transcription system to reverse-transcribe the extracted total tissue RNA into cDNA in time, and then use the method of fluorescent quantitative PCR Acquisition and analysis of gene expression data.

[0031] 4. qPCR

[0032] Primers were synthesize...

Embodiment 3

[0042] Analysis of correlation between YKL-40 transcription level and patient survival and prognosis

[0043] Excel2013 and GraphPadPrism5.0 were used to analyze the YKL-40 gene transcription level in 45 glioblastoma patients, and the YKL-40 gene chip expression data from the TCGA database were analyzed through cBio Cancer GenomicsPortal.

[0044] The results showed that among the collected 45 glioblastoma patients, the transcription level of YKL-40mRNA was significantly negatively correlated with the survival time of the patients (r=0.33, P Figure 4 ); in the TCGA database, the median survival period of glioblastoma patients with high YKL-40 expression was 9.86 months, and the median survival period of patients with low YKL-40 expression was 14.19 months (P=0.0747, n =604)( Figure 5 ); in the TCGA database, the progression-free survival period of glioblastoma patients with high YKL-40 expression was 4.6 months, and the progression-free survival period of patients with low YK...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of human cartilage glycoprotein (YKL-40) as a glioblastoma biomarker. The glioblastoma (Glioblastoma, GBM) patient is low in survival rate and poor in prognosis. Effective biomarker and monitoring method are absent at present. The invention finds that the overall YKL-40 meso-position expression is obviously increased (Fold change=9.483, P<0.0001) by analyzing the YKL-40 mRNA gene expression data of the glioblastoma patient in a TCGA (The Cancer Genome Atlas) database. 45 IV-stage Chinese people glycoprotein clinic samples are further collected, and after qPCR process is adopted for quantitatively analyzing the YKL-40 expression and the prognosis correlation analysis is performed, the YKL-40 mRNA transcriptional level of 41 patients is obviously increased and the patients are short in lifetime and poor in prognosis. The invention analyzes and verifies that the YKL-40 is closely related to the lifetime and poor prognosis, the YKL-40 can be used as a potential glioblastoma biomarker, and a qPCR or protein quantitative monitoring method can be utilized to indicate the lifetime and prognosis of the glioblastoma patient.

Description

technical field [0001] The invention belongs to the field of biomedicine. Clinical application of YKL40, a biomarker related to glioblastoma, in treatment and prognosis monitoring. Background technique [0002] The role of YKL-40 in promoting tumor progression [0003] Human cartilage glycoprotein 39 (YKL-40), a member of the chitinase-like glycoprotein family, was first discovered in cultures of the human osteosarcoma cell line MG-63 [1] . Structural analysis revealed that YKL-40 contains a highly conserved chitin-binding domain, however, it is functionally deficient as a chitinase due to its glutamate-to-leucine mutation in the chitinase catalytic domain [2,3] . Although the physiological role of YKL-40 is not fully understood, it is believed that YKL-40 is involved in the proliferation of connective tissue and the activation of vascular endothelial cells [4-6] . More and more clinical evidences show that abnormal expression of YKL-40 is mainly related to the pathoge...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68G01N33/68G01N33/574
CPCC12Q1/6886C12Q2600/118C12Q2600/158G01N33/57407G01N33/57419G01N33/68
Inventor 不公告发明人
Owner BEIJING TRICISIONBIO THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com